Hisamitsu Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Hisamitsu Pharmaceutical's CEO is Kazue Nakatomi, appointed in May 2015, has a tenure of 9.5 years. directly owns 0.33% of the company’s shares, worth ¥1.10B. The average tenure of the management team and the board of directors is 1.3 years and 10.5 years respectively.

Anahtar bilgiler

Kazue Nakatomi

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	9.5yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	10.5yrs

Son yönetim güncellemeleri

Recent updates

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Oct 17

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Sep 16

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 20

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

Jul 26

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Jul 11

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Jun 27

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Jun 13

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Apr 09

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Mar 18

CEO

Kazue Nakatomi (52 yo)

9.5yrs

Görev süresi

Mr. Kazuhide Nakatomi, also known as Kazue, serves as Chief Executive Officer since May 2019, President since May 2015 & Director since May 2007 at Hisamitsu Pharmaceutical Co. Inc. and served as its Chief...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kazuhide Nakatomi	President	9.5yrs	Veri yok	0.33% ¥ 1.1b
Naruhito Higo	Executive VP	less than a year	Veri yok	Veri yok
Nobuo Tsutsumi	Exe Officer of Legal Affairs	10.5yrs	Veri yok	0.0068% ¥ 22.4m
Kosuke Sugiyama	Executive MD of Human Resources	less than a year	Veri yok	0.018% ¥ 58.2m
Tetsuo Akiyama	Senior Managing Executive Officer	less than a year	Veri yok	Veri yok
Kyu Saito	MD, Executive Officer	no data	Veri yok	0.0095% ¥ 31.3m
Shinichi Murayama	Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director	no data	Veri yok	0.0082% ¥ 26.9m
Mitsutoshi Tsuruta	Senior Executive Officer & GM of Pharmaceutical Business Division	no data	Veri yok	Veri yok
Masaya Okuno	Senior Executive Officer and GM of the Pharmaceuticals & Cosmetics Division	no data	Veri yok	Veri yok
Koji Takiyama	Executive Officer	3.5yrs	Veri yok	0.0041% ¥ 13.4m
Katsuhiko Akiyama	Senior Executive Officer & GM of MN Business Promotion Office	1.8yrs	Veri yok	Veri yok
Tomoya Suzuki	Executive Officer and GM of the Regional Mass Sales Dept of Pharmaceuticals & Cosmetics Division	less than a year	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim: 4530's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kazuhide Nakatomi	President	17.5yrs	Veri yok	0.33% ¥ 1.1b
Nobuo Tsutsumi	Exe Officer of Legal Affairs	10.5yrs	Veri yok	0.0068% ¥ 22.4m
Kosuke Sugiyama	Executive MD of Human Resources	25.5yrs	Veri yok	0.018% ¥ 58.2m
Kyu Saito	MD, Executive Officer	11.5yrs	Veri yok	0.0095% ¥ 31.3m
Shinichi Murayama	Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director	10.5yrs	Veri yok	0.0082% ¥ 26.9m
Koji Takiyama	Executive Officer	3.5yrs	Veri yok	0.0041% ¥ 13.4m
Munehiko Hirano	Standing Corporate Auditor	18.5yrs	Veri yok	0.0027% ¥ 9.0m
Tetsugo Matsuo	Part-time Outside Independent Director	4.5yrs	Veri yok	0.0014% ¥ 4.5m
Yuichiro Anzai	Part-time Outside Independent Director	4.5yrs	Veri yok	Veri yok
Kentaro Watanabe	Part Time Outside Corporate Auditor	1.5yrs	Veri yok	Veri yok
Tamako Watanabe	Part Time Outside Independent Director	1.5yrs	Veri yok	Veri yok

10.5yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4530's board of directors are seasoned and experienced ( 10.5 years average tenure).

Hisamitsu Pharmaceutical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Upcoming dividend of JP¥45.00 per share

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2025 Results on Oct 10, 2024

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024

Upcoming dividend of JP¥42.50 per share

Price target decreased by 15% to JP¥4,250

Third quarter 2024 earnings released: EPS: JP¥48.25 (vs JP¥37.89 in 3Q 2023)

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2024 Results on Jan 11, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of JP¥42.50 per share at 1.8% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2024 Results on Oct 06, 2023

Price target increased by 16% to JP¥4,450

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.57% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024

Full year 2023 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2024 Results on Jul 13, 2023

Full year 2023 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥42.25 per share at 2.1% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2023 Results on Apr 13, 2023

Third quarter 2023 earnings released: EPS: JP¥37.89 (vs JP¥14.91 in 3Q 2022)

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023

Price target increased to JP¥3,700

Less than half of directors are independent

Price target increased to JP¥3,700

Consensus forecasts updated

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2023 Results on Jan 12, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.51% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter Ended August 31, 2022, Payable on Nov. 9, 2022; Provides Dividend Guidance for the full year ending February 28, 2023

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2023 Results on Oct 12, 2022

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter and Full Year Ending February 28, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2023 Results on Jul 07, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2023

Upcoming dividend of JP¥42.00 per share

Upcoming dividend of JP¥42.00 per share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2022 Results on Apr 07, 2022

Consensus EPS estimates fall by 19%

Price target decreased to JP¥3,600

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2022

Second quarter 2022 earnings released: EPS JP¥32.30 (vs JP¥43.82 in 2Q 2021)

Upcoming dividend of JP¥42.00 per share

First quarter 2022 earnings released: EPS JP¥28.90 (vs JP¥1.38 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥113 (vs JP¥228 in FY 2020)

Hisamitsu Pharmaceutical Co., Inc. Provides Earnings Guidance for the Year Ending February 28, 2022

Upcoming Dividend of JP¥41.75 Per Share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2021 Results on Apr 08, 2021

New 90-day high: JP¥6,430

Revenue and earnings miss expectations

Revenue and earnings miss expectations